ArticleThoracic cancer2020
Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer.
Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Prognostic Value of the Lung Immune Prognostic Index (LIPI) in Patients with Renal Cell Carcinoma: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Baseline Gustave Roussy Immune Score and Survival in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemoimmunotherapy.Cancer management and research · 2026Article
- Prognostic utility of baseline ASCL1/INSM1 expression and neutrophil-lymphocyte ratio in unresectable SCLC treated with first-line chemoimmunotherapy with or without radiotherapy.Frontiers of medicine · 2025Article
- Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Article
- Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway.Molecular cancer · 2024Article
- Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer.Cell & bioscience · 2024Review
- Serum albumin and derived neutrophil-to-lymphocyte ratio are potential predictive biomarkers for immune checkpoint inhibitors in small cell lung cancer.Frontiers in immunology · 2024Article
- C-PLAN index as a prognostic factor for patients with previously untreated advanced non-small cell lung cancer who received combination immunotherapy: A multicenter retrospective study.Thoracic cancer · 2023Article
- Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment.Thoracic cancer · 2022Article
- Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer.BMC cancer · 2022Article
- Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy.Thoracic cancer · 2022Article
- Prognostic significance of modified lung immune prognostic index in osteosarcoma patients.Frontiers in genetics · 2022Article
- Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection.Frontiers in surgery · 2022Article
- Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.Cancer management and research · 2022Article
- What Are the Biomarkers for Immunotherapy in SCLC?International journal of molecular sciences · 2021Review
- A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer.Annals of translational medicine · 2021Review
- Article
- Improvement of Diagnostic Accuracy for Pancreatic Cancer with Serum Lactate Dehydrogenase.Cancer management and research · 2021Article
- Prognostic Significance of the Lung Immune Prognostic Index in Patients with Resected Esophageal Squamous Cell Carcinoma.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe lung immune prognostic index (LIPI) is a marker that combines the derived neutrophil-to-lymphocyte ratio (dNLR) and serum lactate dehydrogenase (LDH) level and is a recently reported prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer (NSCLC). However, there are no reports regarding the prognostic value of LIPI in small cell lung cancer (SCLC).
methodsWe retrospectively enrolled 171 patients diagnosed with SCLC and treated at Shinshu University School of Medicine between January 2003 and November 2019. Progression-free survival (PFS) and overall survival (OS) were compared according to LIPI, and we investigated whether LIPI could be a prognostic factor in SCLC using the Kaplan-Meier method and univariate and multivariate Cox models.
resultsThe median OS of the LIPI 0 group was significantly longer than that of the LIPI 1 plus 2 group (21.0 vs. 11.6 months, P < 0.001). The multivariate analysis associated with OS indicated that LIPI 1 plus 2 was an independent unfavorable prognostic factor in addition to poor performance status (2-3), old age (≥ 75 years) and stage (extensive disease [ED]). However, PFS of the LIPI 0 group was not significantly different from that of the LIPI 1 plus 2 group. In ED-SCLC patients, the median PFS and OS of the LIPI 0 group were significantly longer than those of the LIPI 2 group (6.6 vs. 4.0 months, P = 0.006 and 17.1 vs. 5.9 months, P < 0.001, respectively).
conclusionsWe confirmed the prognostic value of LIPI in SCLC, especially ED-SCLC. KEY POINTS: Significant findings of the study: The present study is the first to demonstrate that pretreatment lung immune prognostic index is an independent prognostic factor associated with overall survival for small cell lung cancer. WHAT THIS STUDY ADDS: The utility of the lung immune prognostic index as a prognostic factor for small cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.